Articles From: Synergetics Reports First Quarter of Fiscal Year 2015 Results to Synopsys Co-CEO Aart de Geus to Speak at Morgan Stanley Technology, Media & Telecom Conference


2014/12/10
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1164285&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics Reports First Quarter of Fiscal Year 2015 Results investment picks
2014/12/1
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1162375&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics USA Announces Conference Call to Review First Quarter of Fiscal Year 2015 Results investment picks
2015/2/24
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1177386&ProfileId=051205&sourceType=1 O'FALLON, MO --
Sign-up for Synergetics USA Announces Conference Call to Review Second Quarter of Fiscal Year 2015 Results investment picks
2015/1/8
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the first of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). The randomized, 12-week, double-blind, placebo-controlled pivotal phase 3 CIC trial is evaluating plecanatide 3.0 and 6.0 mg, once-daily oral tablets, in approximately 1350 adult patients with CIC.
Sign-up for Synergy Pharmaceuticals Completes Patient Enrollment for the First Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
2015/1/29
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that it has successfully completed patient enrollment in the second of two pivotal phase 3 trials evaluating the safety and efficacy of two plecanatide doses (3.0 and 6.0 mg) in patients with chronic idiopathic constipation (CIC). Synergy announced that it had completed patient enrollment in the first phase 3 CIC trial on January 8, 2015.
Sign-up for Synergy Pharmaceuticals Completes Patient Enrollment for the Second Pivotal Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation investment picks
2014/12/18
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today the initiation of the first of two planned pivotal phase 3 clinical trials evaluating the safety and efficacy of 3.0 and 6.0 mg plecanatide, once-daily oral tablets, for the treatment of irritable bowel syndrome with constipation (IBS-C). Synergy is also evaluating 3.0 and 6.0 mg doses of plecanatide in two ongoing pivotal phase 3 trials for chronic idiopathic constipation (CIC), scheduled to read out top-line results in second quarter and third quarter 2015.
Sign-up for Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation investment picks
2015/2/3
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), today announced its Chairman and Chief Executive Officer, Dr.
Sign-up for Synergy Pharmaceuticals to Present at Two Upcoming Investment Conferences investment picks
2015/2/4
IBM Among Top Cloud Providers ARMONK, N.Y. , Feb.
Sign-up for Synergy Research Positions IBM as the #1 Hybrid Cloud Provider for the Enterprise investment picks
2015/1/26
Synergy Strips Corp.
Sign-up for Synergy Strips Corp. Acquires Assets of America’s No.1 Brain Health Supplement, FOCUSfactor investment picks
2014/12/8
FDA Clearance for NS3000, a 30 Watt Holmium Laser for the Urology Market ROSEVILLE, Calif.
Sign-up for Syneron Candela Signs Agreement with American Medical Systems to Supply Holmium Laser for Urology investment picks
2015/2/18
New UltraShape Campaign Promises a Flatter Tummy Without Torture IRVINE, Calif.
Sign-up for Syneron Candela's Ultrashape Is Challenging Exercise To Eliminate Stubborn Fat investment picks
2014/12/1
YOKNEAM, Israel , Dec.
Sign-up for Syneron Medical Announces $20 Million Share Repurchase Program investment picks
2015/1/8
Total revenue in the range of $72 to $74 million, up 20% to 24% y/y (pro-forma excluding Syneron Beauty), including approximately 50% product revenue growth in North America Strong UltraShape full commercial launch in U.S. with more than 50 systems sold Successful global launch of PicoWay with approximately $2.5 million in sales from mid-November through the end of the year YOKNEAM, Israel , Jan.
Sign-up for Syneron Medical Announces Preliminary Fourth Quarter 2014 Revenue investment picks
2015/2/12
YOKNEAM, Israel , Feb.
Sign-up for Syneron Medical Appoints William Griffing to Newly Created Position of CEO of Syneron Candela North America investment picks
2015/2/18
Total revenue up 23.7% y/y; North America product revenue up 50.2% y/y Generated $13.3 million in cash from operations Successful commercial launches of UltraShape and PicoWay YOKNEAM, Israel , Feb.
Sign-up for Syneron Medical Reports Record Revenue of $74.1 Million for the Fourth Quarter 2014 investment picks
2015/1/12
Ilan Nacasch, formerly of SodaStream and Procter & Gamble, to lead global marketing and branding for all Syneron-Candela products YOKNEAM, Israel , Jan.
Sign-up for Syneron Medical Strengthens Management Team with Addition of Chief Brand Officer investment picks
2015/2/5
YOKNEAM, Israel , Feb.
Sign-up for Syneron Medical to Participate in the 2015 Leerink Global Healthcare Conference investment picks
2015/2/5
YOKNEAM, Israel , Feb.
Sign-up for Syneron Medical to Report Fourth Quarter 2014 and Full Year 2014 Financial Results on February 18, 2015 investment picks
2015/2/4
By Marta Falconi ZURICH--Syngenta AG (SYT) on Wednesday reported a drop in full-year net income, despite sales growth in Latin America, Asia Pacific and Europe.
Sign-up for Syngenta Profit Dented by Restructuring and Impairments investment picks
2014/12/22
BASEL, Switzerland , December 22, 2014 /PRNewswire/ -- Import approval granted for food and feed use Agrisure Viptera ® offers unrivalled control of above-ground pests Key component of Syngenta's integrated insect control solutions Syngenta today announced that it has received the safety certificate for its Agrisure Viptera ® trait (event MIR162) from China's regulatory authorities, formally granting import approval.
Sign-up for Syngenta Receives Chinese Import Approval for Agrisure Viptera® Corn Trait investment picks
2015/2/4
By Marta Falconi ZURICH--Syngenta AG (SYT) on Wednesday said it expects fluctuating currencies will stifle earnings growth this year, as the company reported a drop in full-year net income despite sales growth in Latin America, Asia Pacific and Europe.
Sign-up for Syngenta Warns of Currency Drag on Earnings--Update investment picks
2015/1/12
SYNNEX Corporation (NYSE: SNX), a leading business process services company, today announced financial results for the fiscal fourth quarter and year ended November 30, 2014.
Sign-up for SYNNEX Corporation Reports Record Revenue and Income for Fiscal 2014 Fourth Quarter and Full Year investment picks
2014/12/29
SYNNEX Corporation (NYSE:SNX), a leading business process services company, will announce fiscal fourth quarter and annual results for the period ended November 30, 2014 after market close on Monday, January 12, 2015.
Sign-up for SYNNEX Corporation to Announce Fiscal Fourth Quarter and Annual Results on January 12, 2015 investment picks
2015/1/28
SYNNEX Corporation (NYSE:SNX), a leading business process services company, announced today its plans to participate in two investor conferences in February.
Sign-up for SYNNEX Corporation to Participate in Stifel and Goldman Sachs Investor Conferences investment picks
2015/1/5
SYNNEX Corporation (NYSE:SNX), a leading business process services company, announced today its plans to participate in the 17 th Annual Needham Growth Conference on January 15, 2015 at the New York Palace Hotel in New York City.
Sign-up for SYNNEX Corporation to Participate in the 17th Annual Needham Growth Conference investment picks
2014/12/16
Enables Delivery of Accurate Sentaurus TCAD Models for Nanowire, FinFET and Tunnel-FET Transistors MOUNTAIN VIEW, Calif.
Sign-up for Synopsys and Imec Expand TCAD Collaboration to 5 nm and Beyond investment picks
2015/2/4
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Announces Earnings Release Date for First Quarter Fiscal Year 2015 investment picks
2014/12/16
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Appoints Janice Chaffin to Board of Directors investment picks
2015/1/7
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Co-CEO Aart de Geus to Speak at 17th Annual Needham Growth Conference investment picks
2015/2/25
MOUNTAIN VIEW, Calif.
Sign-up for Synopsys Co-CEO Aart de Geus to Speak at Morgan Stanley Technology, Media & Telecom Conference investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Synergetics Reports First Quarter of Fiscal Year 2015 Results to Synopsys Co-CEO Aart de Geus to Speak at Morgan Stanley Technology, Media & Telecom Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent